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Identity 
Other names: AAG11; DRAL; FHL-2; SLIM3 
HGNC (Hugo): FHL2 
Location: 2q12.2 
Local order; 91kb telomeric to transforming growth 
factor, beta receptor associated protein 1 (TGFBRAP1). 
DNA/RNA 
Description 
Human FHL2 gene spans around 80kb of genomic 
DNA on the chromosome 2q12-q14 in telomere-to-
centromere orientation. FHL2 promoter contains 
putative transcription factor binding sites for SRF  
 
(serum response factor), NKX2-5, MEF-2, E2F and 
AP-1 (activator protein-1). 
Transcription 
Four transcript variants of FHL2 genes have been 
reported in Entrez Gene (NCBI). These alternative 
spliced transcripts are 1.55-1.91 kb in length, and differ 
in the 5'-UTR only. 
Pseudogene 
No pseudogenes for FHL2 are known. 
Protein 
Description 
The open reading frame encodes a 279 amino acid 
protein with an estimated molecular weight of 32.2kDa. 
FHL2 protein constitutes four and a half  
 
Chromosomal location of FHL2 gene (upper panel) and genomic organization of four FHL2 transcript variants. 
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N-terminal LIM domains. The four complete LIM 
domains extend from amino acid 40-92, 100-153, 162-
217 and 220-275. 
Expression 
In human tissues, FHL2 expression is the most 
abundant in adult heart and ovary, and of low level in 
brain, lung, liver, kidney and intestine. FHL2 is initially 
identified as a downregulated gene in human 
rhabdomyosarcoma cells. However, eleva-ted FHL2 
expression is detected in other cancers, including 
hepatocellular carcinoma, glioblastoma, breast, 
prostate, ovarian, and gastrointestinal cancers. 
Localisation 
Cytoplasm and nucleus. 
Function 
At tissue level, FHL2 plays important roles in the 
development of cardiac circulatory system and 
placenta. It also induces osteoblast and myoblast 
differentiation. At cellular level, FHL2 participates in 
various processes, including cell survival, adhesion, 
motility, transcription and signal trans-duction. At 
molecular level, the LIM domains of FHL2 are double 
zinc finger motifs that physically interact with partner 
proteins to modulate RNA splicing, DNA replication 
and repair. It also fun-ctions as a transcriptional co-
activator for androgen receptor, AP-1, CREB (cAMP 
response element binding protein), CREM (cAMP 
response element modulator), BRCA1 (breast cancer 
1), WT-1 (wilms' tumor), and NF-kB (nuclear factor-
kB). Moreover, FHL2 is a transcriptional co-suppressor 
for ERK2 (extracellular signal regulated kinase 2), SRF 
and FOXO1 (forkhead box O1). 
Homology 
FHL2 belongs to the four-and-a-half-LIM-only protein 
family, which includes FHL1, FHL2, FHL3, FHL4 and 
FHL5 (ACT). Human FHL2 amino acid sequence is 
48.2% identical with FHL1, 53.4% with FHL3, 48.4% 
with mouse FHL4, and 59.1% with FHL5. Orthologs of 
human FHL2 are found in macaque, mouse, rat, bovine, 
dog, chicken, frog, zebrafish, amphioxis, drosophila 
and C. elegans. 
Mutations 
Somatic 
G142A missense mutation, corresponding to Gly48Ser 
within the first LIM domain, is identified in 
heterozygous state in a 49-years-old female dilated 
cardiomyopathy (DCM) patient. This mutation 
abrogates the binding of FHL2 with titin/connectin, a d 
in turn impairs the abnormal recruitment of metabolic 






FHL2 expression is downregulated in rhabdomyo-




In 8 of 10 human liver tumors samples, FHL2 mRNA 
expression is higher than that in matched nontumor 
livers (Wei et al., 2003). In contrast, it is recently 
reported that FHL2 protein is down-regulated in liver 
tumors, as compared with matched nontumor liver 
tissues. In addition, FHL2 inhibits hepatoma cell 
growth in vitro and in nude mice (Ding et al., 2009). 
Ovarian cancer 
Note 
FHL2 protein expression is upregulated in epithelial 
ovarian cancer, as compared with matched normal 
tissues (Gabriel et al., 2004). 
Breast cancer 
Note 
FHL2 is overexpressed in human mammary carci-noma 
samples, compared with normal breast tissues. FHL2 
induces the expression of cell cycle inhibitor 
p21Cip1/Waf1 in MDA-MB 231 breast cancer cells 
(Martin et al., 2007). 
Prognosis 
Patients with tumors expressing low amounts of FHL2 
were characterized by a significantly better survival 
compared to those with high intratumoral FHL2 
expression (Gabriel et al., 2006). 
Prostate cancer 
Note 
FHL2 expression is downregulated by 2- to 4-fold in 
primary prostate cancer relatively to normal tissues for 
five pairs of samples (Kinoshita et al., 2005). Another 
study reports that FHL2 expression is increased in 
prostate adenocarcinoma cells when compared with 
benign epithelial cells. It might be the subcellular 
localization of FHL2 that governs the progression of 
prostate cancer (Muller et al., 2002). Androgen-induced 
FHL2 expression is mediated by SRF (Heemers et al., 
2007). 
Prognosis 
Nuclear, but not cytoplasmic expression of FHL2 
significantly correlates with the recurrence of pros-tate 
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Gastrointestinal cancer 
Note 
FHL2 expression is upregulated in gastric and  
 
colon cancer, compared with matched normal tissues. 
Suppression of FHL2 induces gastric and colon cell 
differentiation, and inhibits cell prolifera-tion and 
expression of oncogenes (survivin, cox-2, hTERT and
c-jun) in vitro. Antisense FHL2 also inhibits 
tumorigenesis of colon cancer cells in xenograft nude 
mice model (Wang et al., 2007). 
Glioma 
Note 
The mRNA level of FHL2 is elevated in both low (3 of 
6) and high (11 of 13) grade glioma patient samples. 
FHL2 induces glioblastoma cell prolifera-tion and 
migration in vitro, and promotes tumori-genesis in 
glioblastoma xenograft nude mice model. 
Overexpression of FHL2 decreases mRNA levels of 
p53 and its downstream proapoptotic genes, and 
enhances promoter activities of AP-1, human 
telomerase reverse transcriptase and survivin genes (Li 
et al., 2008). 
References 
Genini M, Schwalbe P, Scholl FA, Remppis A, Mattei MG, 
Schäfer BW. Subtractive cloning and characterization of DRAL, 
a novel LIM-domain protein down-regulated in 
rhabdomyosarcoma. DNA Cell Biol. 1997 Apr;16(4):433-42 
Chan KK, Tsui SK, Lee SM, Luk SC, Liew CC, Fung KP, Waye 
MM, Lee CY. Molecular cloning and characterization of FHL2, 
a novel LIM domain protein preferentially expressed in human 
heart. Gene. 1998 Apr 14;210(2):345-50 
Müller JM, Metzger E, Greschik H, Bosserhoff AK, Mercep L, 
Buettner R, Schüle R. The transcriptional coactivator FHL2 
transmits Rho signals from the cell membrane into the nucleus. 
EMBO J. 2002 Feb 15;21(4):736-48 
Wei Y, Renard CA, Labalette C, Wu Y, Lévy L, Neuveut C, 
Prieur X, Flajolet M, Prigent S, Buendia MA. Identification of 
the LIM protein FHL2 as a coactivator of beta-catenin. J Biol 
Chem. 2003 Feb 14;278(7):5188-94 
Gabriel B, Mildenberger S, Weisser CW, Metzger E, Gitsch G, 
Schüle R, Müller JM. Focal adhesion kinase interacts with the 
transcriptional coactivator FHL2 and both are overexpressed in 
epithelial ovarian cancer. Anticancer Res. 2004 Mar-
Apr;24(2B):921-7 
Kinoshita M, Nakagawa T, Shimizu A, Katsuoka Y. Differently 
regulated androgen receptor transcriptional complex in 
prostate cancer compared with normal prostate. Int J Urol. 
2005 Apr;12(4):390-7 
Gabriel B, Fischer DC, Orlowska-Volk M, zur Hausen A, 
Schüle R, Müller JM, Hasenburg A. Expression of the  
transcriptional coregulator FHL2 in human breast cancer: a 
clinicopathologic study. J Soc Gynecol Investig. 2006 
Jan;13(1):69-75 
Johannessen M, Møller S, Hansen T, Moens U, Van Ghelue 
M. The multifunctional roles of the four-and-a-half-LIM only 
protein FHL2. Cell Mol Life Sci. 2006 Feb;63(3):268-84 
Kahl P, Gullotti L, Heukamp LC, Wolf S, Friedrichs N, 
Vorreuther R, Solleder G, Bastian PJ, Ellinger J, Metzger E, 
Schüle R, Buettner R. Androgen receptor coactivators lysine-
specific histone demethylase 1 and four and a half LIM domain 
protein 2 predict risk of prostate cancer recurrence. Cancer 
Res. 2006 Dec 1;66(23):11341-7 
Arimura T, Hayashi T, Matsumoto Y, Shibata H, Hiroi S, 
Nakamura T, Inagaki N, Hinohara K, Takahashi M, Manatsu 
SI, Sasaoka T, Izumi T, Bonne G, Schwartz K, Kimura A. 
Structural analysis of four and half LIM protein-2 in dilated 
cardiomyopathy. Biochem Biophys Res Commun. 2007 May 
25;357(1):162-7 
Heemers HV, Regan KM, Dehm SM, Tindall DJ. Androgen 
induction of the androgen receptor coactivator four and a half 
LIM domain protein-2: evidence for a role for serum response 
factor in prostate cancer. Cancer Res. 2007 Nov 
1;67(21):10592-9 
Kleiber K, Strebhardt K, Martin BT. The biological relevance of 
FHL2 in tumour cells and its role as a putative cancer target. 
Anticancer Res. 2007 Jan-Feb;27(1A):55-61 
Martin BT, Kleiber K, Wixler V, Raab M, Zimmer B, Kaufmann 
M, Strebhardt K. FHL2 regulates cell cycle-dependent and 
doxorubicin-induced p21Cip1/Waf1 expression in breast 
cancer cells. Cell Cycle. 2007 Jul 15;6(14):1779-88 
Wang J, Yang Y, Xia HH, Gu Q, Lin MC, Jiang B, Peng Y, Li 
G, An X, Zhang Y, Zhuang Z, Zhang Z, Kung HF, Wong BC. 
Suppression of FHL2 expression induces cell differentiation 
and inhibits gastric and colon carcinogenesis. 
Gastroenterology. 2007 Mar;132(3):1066-76 
Li M, Wang J, Ng SS, Chan CY, Chen AC, Xia HP, Yew DT, 
Wong BC, Chen Z, Kung HF, Lin MC. The four-and-a-half-LIM 
protein 2 (FHL2) is overexpressed in gliomas and associated 
with oncogenic activities. Glia. 2008 Sep;56(12):1328-38 
Ding L, Wang Z, Yan J, Yang X, Liu A, Qiu W, Zhu J, Han J, 
Zhang H, Lin J, Cheng L, Qin X, Niu C, Yuan B, Wang X, Zhu 
C, Zhou Y, Li J, Song H, Huang C, Ye Q. Human four-and-a-
half LIM family members suppress tumor cell growth through a 
TGF-beta-like signaling pathway. J Clin Invest. 2009 
Feb;119(2):349-61 
This article should be referenced as such: 
Lin M, Cheung W. FHL2 (four and a half LIM domains 2). Atlas 
Genet Cytogenet Oncol Haematol. 2010; 14(4):383-385. 
